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ARTICLE OPEN
Determinants of initial inhaled corticosteroid use in patients
with GOLD A/B COPD: a retrospective study of UK general
practice
James D. Chalmers1, Abigail Tebboth2, Alicia Gayle2, Andrew Ternouth2 and Nick Ramscar2
Initial use of inhaled corticosteroid therapy is common in patients with Global Initiative for Chronic Obstructive Lung Disease
(GOLD) A or B chronic obstructive pulmonary disease, contrary to GOLD guidelines. We investigated UK prescribing of inhaled
corticosteroid therapy in these patients, to identify predictors of inhaled corticosteroid use in newly diagnosed chronic obstructive
pulmonary disease patients. A cohort of newly diagnosed GOLD A/B chronic obstructive pulmonary disease patients was identiﬁed
from the UK Clinical Practice Research Datalink (June 2005–June 2015). Patients were classiﬁed by prescribed treatment, with those
receiving inhaled corticosteroid-containing therapy compared with those receiving long-acting bronchodilators without inhaled
corticosteroid. In all, 29,815 patients with spirometry-conﬁrmed chronic obstructive pulmonary disease were identiﬁed. Of those
prescribed maintenance therapy within 3 months of diagnosis, 63% were prescribed inhaled corticosteroid-containing therapy vs.
37% prescribed non-inhaled corticosteroid therapy. FEV1% predicted, concurrent asthma diagnosis, region, and moderate
exacerbation were the strongest predictors of inhaled corticosteroid use in the overall cohort. When concurrent asthma patients
were excluded, all other co-variates remained signiﬁcant predictors. Other signiﬁcant predictors included general practitioner
practice, younger age, and co-prescription with short-acting bronchodilators. Trends over time showed that initial inhaled
corticosteroid prescriptions reduced throughout the study, but still accounted for 47% of initial prescriptions in 2015. These results
suggest that inhaled corticosteroid prescribing in GOLD A/B patients is common, with signiﬁcant regional variation that is
independent of FEV1% predicted.
npj Primary Care Respiratory Medicine  (2017) 27:43 ; doi:10.1038/s41533-017-0040-z
INTRODUCTION
Current international guidelines for chronic obstructive pulmonary
disease (COPD) recommend long-acting inhaled bronchodilators,
including β2-agonists (LABA) and anti-muscarinic agents (LAMA),
as maintenance therapies.1 These agents can be given as
monotherapy, as combination bronchodilators, or in combination
with inhaled corticosteroids (ICS) for the symptomatic manage-
ment of COPD. The Global Initiative for Chronic Obstructive Lung
Disease (GOLD) 2016 guidelines recommend that ICS therapy is
reserved for COPD patients with severe/very severe disease and/or
frequent or severe exacerbations.1 They do not recommend ICS
therapy for GOLD stage A or B COPD patients. Similarly, NICE
clinical guidelines for COPD (CG101) recommend ICS in combina-
tion with LABA if FEV1 < 50% predicted, and ICS in combination
with LAMA + LABA for patients who remain breathless or have
exacerbations despite taking LABA + ICS.2 However, a signiﬁcant
dissociation has been reported between guideline recommenda-
tions and clinical practice,3, 4 with common use of ICS in patients
with GOLD stage A and B COPD.5 Further research also suggests
that many patients are prescribed ICS therapy at their initial COPD
diagnosis, regardless of disease severity.6 Recent randomised
controlled trials show combined bronchodilator treatment is
superior to ICS/LABA in lung function improvement, symptomatic
beneﬁt, and reduction in exacerbations, including in patients with
GOLD stage B disease.7–9 ICS therapy is important in the treatment
of asthma-COPD overlap (ACO), and ICS combinations should be
the default treatment for patients with features of both asthma
and COPD.1, 10 They are not appropriate, however, for patients
with GOLD A and B COPD based on the available treatment
guidelines and clinical evidence.
Inappropriate ICS treatment carries important risks, with
randomised controlled trials demonstrating an increased inci-
dence of pneumonia, fractures, and other side effects compared
to long-acting bronchodilators.11–15 Reducing inappropriate ICS
prescribing in early-stage COPD is therefore a key quality
improvement objective, but one that has not been achieved
despite a consistent message from national and international
guidelines. It is therefore essential to understand what drives
initial use of ICS in early COPD; as such the aim of this study was to
identify factors that were independently associated with UK
prescribers’ decisions to prescribe ICS therapies in patients with
early COPD.
RESULTS
A total of 29,815 patients with spirometry-conﬁrmed COPD of
GOLD stage A or B were identiﬁed during the study period (see
Supplementary Table S1 and Supplementary Fig. S1 in
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the Supplementary Information for baseline characteristics and
patients included in the study). There were slightly more male
than female patients (54 vs. 46%), and the most common age
category was 60–69 years (mean age 67 years). The most common
comorbidities were concurrent asthma (20%), diabetes (9%),
myocardial infarction (7%), and osteoporosis/osteopenia (7%).
Eosinophilia was recorded as present in 23% of patients. The
majority of patients were current or ex-smokers (83%) and 1% of
patients had one moderate exacerbation in the year prior to
diagnosis.
Fewer patients were observable in the cohort in the latter years
of the study (2009–2015); this is most likely due to variation in the
frequency of data uploading by practices to the Clinical Practice
Research Datalink (CPRD). The region with the largest volume of
data was North West England, although all UK regions were
represented in the study.
The therapies prescribed to patients in the overall cohort within
3 months of COPD diagnosis are displayed in Fig. 1. The number of
patients initially prescribed ICS-containing therapy is considerably
higher than the number prescribed long-acting, non-ICS therapy
(34 vs. 20%, respectively).
Of the patients prescribed maintenance therapy (i.e., excluding
patients prescribed short-acting therapy or receiving no treat-
ment), an average 63% were prescribed ICS-containing therapy vs.
37% prescribed non-ICS therapy. There was a strong trend to
reduction of initial ICS prescribing over time, falling from 77% in
2005 to 47% at the end of the study (p < 0.0001). The greatest
proportion of patients was prescribed ICS-containing maintenance
therapy if initiating treatment prior to 2009 (Fig. 2).
Baseline characteristics in the ICS group were compared with
the non-ICS group (Table 1). Patients in the ICS group were slightly
more likely to be female than the non-ICS group (48 vs. 46%
female; p = 0.043), were likely to be younger (p < 0.0001), and
more likely to be diagnosed in the earlier years of the study (p <
0.0001). Patients in the ICS group were also more likely to be
diagnosed with concurrent asthma (35 vs. 12%; p < 0.0001) and
have moderate exacerbations in the year prior to diagnosis (2 vs.
1%; p = 0.0004) and less likely to be current or ex-smokers (81 vs.
86%; p < 0.0001) or have a history of myocardial infarction (6.4 vs.
7.5%; p = 0.006).
These variables were tested in a logistic regression analysis to
identify the factors that affect prescribing of ICS-containing
therapy. In the overall cohort, FEV1% predicted (p = 0.0002),
moderate exacerbation in the year prior to diagnosis (p =
0.0004), UK region (p < 0.0001), age group (p = 0.0017), year of
diagnosis (p < 0.0001), co-prescription of short-acting beta-ago-
nists (SABA)/short-acting muscarinic antagonists (SAMA) therapy
(p < 0.0001), concurrent asthma (p < 0.0001), historic asthma (p =
0.0006), eosinophilia (p = 0.0466), and current/ex-smoker (p <
0.0001) were all signiﬁcantly associated with probability of ICS
prescribing (Fig. 3). General Practitioner (GP) practice was also
signiﬁcantly associated with likelihood of ICS prescribing (p <
0.001); however, this could not be included in the model due to
the small number of patients in many practices. Gender (p =
0.3635), stroke (p = 0.9763), myocardial infarction (p = 0.1043),
diabetes (p = 0.8596), osteoporosis/osteopenia (p = 0.7969), history
of pneumonia (p = 0.133), and body mass index (BMI) (p = 0.4792)
were not signiﬁcantly associated with ICS prescribing. After
checking residuals, there were no violations of model
assumptions.
A second analysis was also conducted, excluding patients with
concurrent asthma. The proportion of patients in the ICS and non-
ICS groups, as well as those prescribed SAMA/SABA therapy or no
treatment, is shown in Supplementary Fig. S2 in the Supplemen-
tary Information. Of those prescribed maintenance therapy, 44%
were prescribed non-ICS therapy and 56% were prescribed ICS-
containing therapy.
Logistic regression analysis in the cohort excluding patients
with concurrent asthma showed that UK region (p < 0.0001), age
group (p = 0.0045), year of diagnosis (p < 0.0001), FEV1% predicted
(p < 0.0001), moderate exacerbation in the year prior to diagnosis
(p = 0.0002), co-prescription of SABA/SAMA therapy (p < 0.0001),
historic asthma (p = 0.0004), eosinophilia (p = 0.025), and current/
ex-smoker (p < 0.0001) were still signiﬁcantly associated with
probability of ICS prescribing (Fig. 4).
A third analysis was conducted in the group of patients with
possible ACO (i.e., COPD with asthma diagnosed in the previous 5
years). Logistic regression analysis in this cohort showed that UK
region (p = 0.007), year of diagnosis (p < 0.0001), co-prescription of
short-acting therapy (p < 0.0001), history of stroke (p = 0.0202),
and current/ex-smoker (p = 0.0021) were signiﬁcantly associated
with probability of ICS prescribing (Supplementary Fig. S3).
Sensitivity analysis
FEV1% predicted (as a continuous variable) and year of diagnosis
were included as interaction terms in the model to determine if
these varied signiﬁcantly by region, and if they could be
responsible for the differences in ICS prescribing by region.
FEV1% predicted was found to be statistically insigniﬁcant (p =
0.1372), whereas year of diagnosis was signiﬁcant (p < 0.001). The
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interaction between eosinophilia and concurrent and historic
asthma was also investigated. Controlling for all variables, having
baseline eosinophilia and concurrent (p = 0.6002) or historic
asthma (p = 0.3849) was not associated with the odds of
prescribing an ICS-containing therapy.
A third sensitivity analysis was conducted comparing predictors
of ICS prescribing in diagnoses before and after 2009. This cut-off
was chosen to investigate the impact of publication of the results
of the TORCH study, which ﬁrst identiﬁed the link between ICS use
and pneumonia, leaving reasonable time to allow for implementa-
tion and recording in CPRD.11 Region, co-prescription with SABA/
SAMA, concurrent and historic asthma, and smoker/ex-smoker
were signiﬁcant predictors both before and after 2009. FEV1%
predicted, moderate exacerbations, and year of diagnosis became
signiﬁcant after 2009, whereas age group and myocardial
infarction were only signiﬁcant pre-2009.
DISCUSSION
Main ﬁndings
This study suggests that a large number of patients with GOLD
stage A or B COPD are prescribed ICS-containing therapy within
3 months of diagnosis. Over the duration of the study, around
twice the number of patients were prescribed ICS-containing
therapy rather than long-acting bronchodilators. When patients
with concurrent asthma were excluded, the number of patients in
the ICS group was still greater than the number in the non-ICS
group (56 vs. 44% of those prescribed maintenance therapy). This
suggests the need for major changes in UK prescribing practices in
order to reduce inappropriate ICS use. The 2017 GOLD strategy
has recently been published and reduces further the role of ICS by
removing lung function from the criteria for GOLD C/D.16 Our
analysis suggests that a major shift in prescribing will be required
before UK practice is reﬂective of either the 2016 or 2017 GOLD
strategy or the NICE guidelines.1, 2, 16 Trends over time show that
prescribing practice is becoming more aligned with GOLD 2016
guidelines; ICS maintenance therapy prescriptions reduced from 77%
in 2005 to 47% in 2015. This could reﬂect changes over the period
of the study, including increased knowledge of side effects related to
ICS use, such as pneumonia, fractures, osteoporosis, cataracts,
tuberculosis, early onset diabetes, and bruising.11, 14, 15, 17, 18
It may also reﬂect the more recent availability of LAMA/LABA
ﬁxed-dose combinations, together with supporting clinical data
that show they improve FEV1 and breathlessness symptoms and
Table 1. Baseline characteristics of patients in the ICS and non-ICS
groups
Characteristic ICS group Non-ICS
group
p-value
N % N %
All patients 10,219 63.3 5930 36.7
Gender (% male) 5346 52.3 3200 54.0 0.043a
Age
40–49 years 778 7.6 329 5.5 <0.0001b
50–59 years 1977 19.3 1063 17.9
60–69 years 3389 33.2 1979 33.4
70–79 years 2848 27.9 1819 30.7
80–89 years 1149 11.2 708 11.9
>90 years 78 0.8 32 0.5
Year of diagnosis
2005 601 77.4 175 22.6 <0.0001b
2006 1332 76.6 408 23.4
2007 1309 75.0 437 25.0
2008 1300 72.1 503 27.9
2009 1241 67.0 610 33.0
2010 1105 61.0 707 39.0
2011 1051 56.3 815 43.7
2012 922 54.5 771 45.5
2013 704 48.4 750 51.6
2014 527 46.2 613 53.8
2015 127 47.4 141 52.6
Comorbidities
Asthma
Historic 331 3.2 162 2.7 0.0709
Concurrent 3568 34.9 730 12.3 <0.0001
Stroke 311 3.0 195 3.3 0.389
MI 651 6.4 445 7.5 0.006
Diabetes 936 9.2 565 9.5 0.437
Osteoporosis/osteopenia 723 7.1 457 7.7 0.137
Eosinophilia 2514 24.6 1386 23.4 0.079
Pneumonia 360 3.5 193 3.3 0.366
Smoking (current or ex)c 8229 80.5 5112 86.2 <0.0001
BMI
Missing 55 0.5 44 0.7 0.9995
Underweight 379 3.7 235 4.0
Normal 3360 32.9 1936 32.6
Overweight 3640 35.6 2081 35.1
Obese 2785 27.3 1634 27.6
FEV1% predicted
80–100% (GOLD 1) 3433 33.6 1871 31.6 0.0077
50–80% (GOLD 2) 6786 66.4 4059 68.4
Moderate exacerbationsd 157 1.5 52 0.9 0.0004
Region
North East 194 1.9 173 2.9 <0.0001
North West 1525 14.9 865 14.6
Yorkshire and The Humber 284 2.8 118 2.0
East Midlands 273 2.7 76 1.3
West Midlands 932 9.1 500 8.4
East of England 700 6.8 329 5.5
Table 1 continued
Characteristic ICS group Non-ICS
group
p-value
N % N %
South West 901 8.8 409 6.9
South Central 986 9.6 601 10.1
London 980 9.6 483 8.1
South East Coast 1005 9.8 508 8.6
Northern Ireland 539 5.3 328 5.5
Scotland 770 7.5 750 12.6
Wales 1130 11.1 790 13.3
BMI body mass index, FEV1 forced expiratory volume in 1 s, GOLD Global
Initiative for Chronic Obstructive Lung Disease, MI myocardial infarction
Bold values indicate statistical signiﬁcance
a Chi-squared test
b Cochran Armitage test for trend
c Ex-smoker and current smoker were pooled due to limitations in CPRD for
distinguishing between these two groups
d In the year prior to COPD diagnosis (the index date)
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reduce exacerbations compared to ICS/LABA therapy in popula-
tions including GOLD B patients.7–9, 19 ICS have a role to play
in patients who continue to experience exacerbations after
treatment with bronchodilators.1 However, the overall results
show that there is still a striking excess use of ICS in patients with
GOLD A/B COPD, which persists in spite of accumulating evidence
that there are safer and more efﬁcacious alternatives in
bronchodilator treatment. This disconnect between evidence
and practice necessitates a clear understanding of what drives
ICS prescribing practices.
Logistic regression analysis highlighted some factors that may
be driving therapy decisions in these patients. In the overall
cohort, FEV1% predicted, moderate exacerbation, UK region, age
group, year of diagnosis, co-prescription of short-acting therapy,
concurrent asthma, historic asthma, eosinophilia, and smoking
status were signiﬁcantly associated with ICS prescribing. When
patients with concurrent asthma were excluded from the analysis,
all other variables remained signiﬁcant predictors. These pre-
dictors have also changed over the study duration, with FEV1%
predicted, moderate exacerbations, and year of diagnosis becom-
ing signiﬁcant after 2009, suggesting prescribing drivers are
changing with time. It is also interesting to note that osteoporosis,
diabetes, and pneumonia did not drive reduced ICS use, despite
being known side effects of long-term ICS use.11, 14, 15, 17, 18
These results provide some insight and allow some speculation
on how ICS therapies are currently being used. FEV1 and history of
exacerbations are markers of the severity and activity of COPD.
Our results suggest that patients with more severe COPD and
patients with a history of one exacerbation are more likely to
receive ICS. This may reﬂect a lack of knowledge of the cut-offs
used in GOLD guidelines to determine ICS use (FEV1 < 50%
predicted and >1 exacerbation) or a lack of conﬁdence in
bronchodilators to prevent exacerbations despite available
evidence to the contrary.7–9, 19 The strong association with
asthma suggests one of two possibilities: that the presence of ACO
is very common and ICS is being used appropriately in those
patients where both conditions are present, or that diagnostic
confusion between these two conditions is leading to overuse of
ICS as physicians look to cover both possibilities. Confusion would
be understandable in primary care, as there is no gold standard
test to distinguish between asthma and COPD, and diagnosis is
reliant on spirometry.
UK region was also a signiﬁcant predictor of ICS prescribing in
patients with GOLD A or B COPD and we also identiﬁed clear
patterns within regions suggesting that particular GP practices
were high ICS users compared to others. This suggests a strong
inﬂuence of personal prescribing preferences, local guidelines,
and local culture in determining ICS use.20 In North East England
and Scotland, patients are less likely to receive an initial
prescription for ICS combinations than the comparator region
(Wales). In the remaining regions, patients are more likely to
receive ICS-containing therapy, with up to 1.7 times increased
probability of prescription in three regions (East Midlands, South
West, and South East Coast; see Fig. 5). This variation could not be
explained by differences in disease severity, as FEV1% predicted
was not signiﬁcantly different between regions (p = 0.1372). Some
centres contributed more data in the earlier or later years of the
study and so some of the regional data may be biased by changes
in prescribing trends over time. Yorkshire and The Humber and
East Midlands, for example, were skewed towards the earlier years
of the study when ICS prescribing was more frequent (Supple-
mentary Fig. S4). However, it does not explain all the variations as
Scotland shows very similar distribution to Wales, and the North
East had low rates of ICS prescribing despite having the majority
of its data from the earlier years of the study. Variation in
respiratory care between UK regions is being monitored by the
NHS as part of the Right Care and Atlas of Variation initiatives. The
latest report showed considerable variation in a number of metrics
related to respiratory diseases, including a seven-fold difference in
the rate of COPD emergency admissions to hospital.21 This is
consistent with our ﬁnding of regional variation in prescribing
behaviour, and highlights the importance placed on unwarranted
variation by the NHS.
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Other signiﬁcant predictors show that younger patients, with
lower likelihood of being current or ex-smokers, were more likely
to be prescribed ICS-containing therapy. This is highly suggestive
of a diagnostic overlap with chronic asthma. Patients with historic
asthma were also more likely to be treated with ICS. Improving
diagnosis of asthma and clear guidance around the potential
overlap between asthma and COPD could therefore lead to a
reduction in the number of prescriptions of ICS therapy to patients
diagnosed with mild or moderate COPD. Asthma diagnosis is a
topic that is currently being considered by the National Institute
for Health and Care Excellence, with an asthma diagnosis and
monitoring guideline currently in development. This guideline
could help GPs with a more systematic approach to the diagnosis
of asthma and in turn with conﬁdence in prescribing maintenance
therapy to patients with mild or moderate COPD.
The ﬁnding that blood eosinophilia was associated with ICS use
is intriguing. While this may be linked to asthma, eosinophilia
remained a signiﬁcant predictor of ICS use even after the exclusion
of patients with a diagnosis of asthma. Although recent post hoc
analyses of randomised controlled trials suggest that blood
eosinophilia can identify a subgroup of patients that are
responsive to ICS,22–24 there is no evidence that practitioners are
currently using eosinophil counts to guide ICS use. This suggests
that there are clinical characteristics associated with eosinophilia
that lead physicians to prefer the use of ICS, independent of
asthma diagnosis.
Interpretation of ﬁndings in relation to previously published work
Our ﬁndings are consistent with previous studies on prescribing in
COPD, which suggest that around 50% of patients with COPD are
treated with ICS therapy.4, 25 A recent UK-based study by Gruffyd-
Jones et al. also noted high prescribing rates of ICS therapies and
major differences between actual prescribing and guideline
recommendations.4 However, some differences exist, in terms of
data source (CPRD vs. the Optimum Patient Database), time period
(2005–2015 vs. 1997–2013), and main focus (initial ICS prescribing
vs. initial prescription of any COPD therapy). These led to some
differences in prescriptions recorded; e.g., we saw greater use of
long-acting bronchodilators and an overall decrease in ICS-
containing prescriptions over time, which was not observed in
Gruffyd-Jones et al. We were also able to include variables that
were not previously studied, including co-morbidities (osteoporo-
sis/osteopenia, diabetes, cardiac disease, and eosinophilia) and
demographic variables (UK region and GP practice). We were
therefore able to identify that UK region and GP practice are both
signiﬁcant predictors of ICS prescription, and that these are
independent of lung function.
This study considers initial prescriptions of ICS therapy to
patients with mild/moderate COPD, which is one aspect of reducing
inappropriate use of ICS. Another aspect of addressing this is the
safe withdrawal of ICS therapy in appropriate patients, a topic that
has been considered by other authors. Two recent randomised
controlled trials, the largest being the WISDOM study and a real-life
prospective study, have shown that ICS can be safely withdrawn in
certain patients, and that this withdrawal may lead to reduction in
ICS side effects such as risk of pneumonia.19, 26–28 Practical guides
and algorithms have also been proposed to enable the withdrawal
of ICS in appropriate patients, based on the currently available
evidence.29, 30 The results of our study should be considered
alongside the literature describing withdrawal of ICS, to provide a
more complete picture of potential strategies for using main-
tenance therapy to maximise symptom relief and prevent harm in
patients with COPD.
Strengths and limitations of this study
Although CPRD is a well-recognised source for studies such as this,
there are some limitations to the analysis. First, variables of
interest are not always available in the database; we used medical
research council dyspnoea score to calculate GOLD stage, as COPD
CAT score was not available. Second, diagnoses are dependent on
the physician entering the data and may not be standardised
across the sample, although the impact of this is likely to be low as
CPRD recording of COPD has been studied and found to be
accurate.31 We are also not able to assess the effect of access or
skill in spirometry on ICS prescribing, which will be variable across
the UK, as having recorded spirometry data is required to allow
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GOLD A/B classiﬁcation and hence inclusion in the study. Third,
data are not available to the same extent and level of detail in all
UK regions, as some areas have a higher COPD prevalence and
some upload data on a more regular basis than others. However,
as these differences occur on a random basis, this is less likely to
lead to bias or affect the direction of the results. Finally, our study
was based on GOLD classiﬁcation, as this is well deﬁned and
relatively easy to study in CPRD. This could be a limitation, as not
all GPs are familiar with the GOLD recommendations and some
may have greater familiarity with the NICE guidelines, which are
older and do not give as clear guidance for patient segmentation.2
However, as discussed above, neither NICE nor GOLD recommend
use of ICS in patients with mild/moderate COPD.1, 2, 16 The study
results should therefore be relevant to practices following NICE or
GOLD recommendations.
Implications for future research, policy, and practice
The results of this study highlight some aspects of the manage-
ment of COPD in clinical practice, which may have implications for
future policy. The regional variation in prescribing, for example, is
a trend that may warrant examination and monitoring at national
level, as this seems to be unrelated to clinical characteristics such
as lung function. Unwarranted variation in the management of
other primary care diseases has resulted in inclusion of new
measures in the quality and outcomes framework, such as the
inclusion of the eight care processes for diabetes.32 This may not
be directly applicable for prescribing behaviours, given the
number of factors inﬂuencing these decisions, but it does
highlight the impact of national monitoring in inﬂuencing
individual behaviour. Local initiatives, such as audits or reviews,
could also help inﬂuence prescribing in order to improve
adherence to guidelines and reduce the regional and local
variation seen in our study.
As noted earlier, the GOLD 2017 strategy has recently been
published, with a further reduced role for ICS.16 As a result, further
research into what will happen in clinical practice following these
new recommendations would also be interesting.
Conclusions
A large proportion of patients with GOLD A or B COPD are given
initial prescription of ICS therapy outside of guidelines in the UK.
This varies according to differences in local prescribing practices
(at practice and regional level), independently of lung function.
The number of prescriptions outside of guidelines has decreased
over recent years, possibly due to the availability of an alternative
to ICS in terms of LABA/LAMA combinations and a greater
awareness of adverse effects, but further work is still needed to
ensure that the majority of patients are treated according to
evidence-based guidelines.
METHODS
Study design
We conducted a retrospective descriptive longitudinal study analysing
data obtained from the UK CPRD. The CPRD provides a database of
anonymised longitudinal clinical records from general practice, covering
689 GP practices in the UK, with 3.9 million people available for
observation at the start of the study. The geographical distribution is
representative of the UK population,33 and several studies have conﬁrmed
the high quality of the data and completeness of the clinical records.31, 34–37
As such it is recognised as a reliable source for investigating UK general
practice and prescribing, and has been used in over 1500 publications to
date (https://www.cprd.com/home/).
Fig. 5 Odds of ICS prescription at COPD diagnosis by UK region. Created by the authors using SAS software version 9.4
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Population
Patients of interest were those with a new diagnosis of GOLD A or B COPD
registered at a CPRD practice during the study period (June 2005–June
2015). Patients also had to be aged 40 years or over at the date of
diagnosis with at least 1 year of data prior to index entry. As the objective
was to study the ﬁrst prescription for maintenance therapy, we excluded
patients already receiving maintenance treatment at study entry. Patients
were also excluded if there was insufﬁcient information in CPRD to conﬁrm
COPD diagnosis, or to calculate baseline GOLD stage. For further inclusion
and exclusion criteria and deﬁnitions used, see Supplementary Table S2 in
the Supplementary Material.
Analysis
Patients were allocated to groups, based on the therapies they received
within the ﬁrst 3 months following COPD diagnosis. These groups included
ICS-containing therapy (ICS only, ICS + LAMA, ICS + LABA, and ICS + LAMA
+ LABA), non-ICS-containing therapy (LAMA, LABA, and LAMA + LABA),
short-acting therapy only (SABA or SAMA only), and none of the above
(indicating no therapy of interest prescribed). Baseline data, including
comorbidities and demographic information, were analysed descriptively.
Variables of interest were summarised and compared between the ICS and
non-ICS groups, including age, gender, smoking status, baseline BMI, year
of COPD diagnosis, osteoporosis/osteopenia, diabetes, cardiac disease,
historical or concurrent diagnosis of asthma, peripheral blood eosinophilia
(deﬁned using Read codes or a record of blood eosinophil count >0.4 ×
109/L), FEV1/FVC ratio, FEV1% predicted, UK region, GP practice, moderate
exacerbation in the year prior to diagnosis, and history of pneumonia.
These were identiﬁed by Read codes (see Supplementary Table S5 in
the Supplementary Information). FEV1% predicted, FEV1/FVC ratio, and
eosinophilia Read codes were conﬁrmed using additional test information
as described in Supplementary Table S6 (Supplementary Information).
FEV1% predicted was capped at 100% for data quality purposes, as we
cannot be sure of the accuracy of values above this point. Current and ex-
smokers were pooled due to limitations in CPRD for distinguishing
between these two groups. Statistical analysis was also carried out for
baseline characteristics: gender, region, and comorbidities were compared
using χ² tests; age group, year of diagnosis, and severity of airway
obstruction were compared using Cochrane Armitage tests for trend (both
with an α = 0.01).
Logistic regression analysis was used to investigate which factors affect
prescribing of ICS-containing therapy. Variables were chosen for the model
using a backwards stepwise method of selection with inclusion criteria of
p < 0.05. Validity of the ﬁnal model was assessed, and there were no
violations of model assumptions after checking residuals. We also
conducted sensitivity analysis to investigate interaction effects of
suspected related variables, including: UK region and FEV1; UK region
and year of diagnosis; and eosinophilia and concurrent or historic asthma.
Data were extracted using the online version of CPRD (CPRD-GOLD), and
analysed using SAS software version 9.4. Missing data that occurred in
covariates or descriptive variables were classiﬁed as their own level.
Variables with >75% missing data were excluded from the analysis, with
the exception of baseline characteristics.
Data availability
The data sets generated and analysed during this study are available from
the corresponding author on reasonable request.
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